News | Ultrasound Women's Health | February 05, 2026

BrightHeart's B-Right AI platform is now available through GE Healthcare's Voluson Solution Store.

BrightHeart to Collaborate with Voluson Solution Store to Provide AI Support Across Full Prenatal Ultrasound Exams

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B-Right AI Platform through GE HealthCare’s Voluson Solution Store, bringing advanced AI support directly into routine prenatal care. The addition of this AI platform to the Voluson Solution store is poised to improve early detection of congenital defects, reduce diagnostic uncertainty and ultimately support better outcomes for clinicians, expectant parents and their babies.

This collaboration combines BrightHeart’s innovative AI technology with GE HealthCare’s trusted Voluson ecosystem through the Voluson Solution Store — the first digital marketplace for Women’s Health ultrasound, available in the U.S. and Europe. Together, the companies are helping to democratize access to expert‑level prenatal care by making clinically validated AI for congenital defect screening and full scan support available to Voluson ultrasound users.

Supported by strong clinical evidence — including two recent publications in The Green Journal -— and developed with leading fetal cardiology and maternal and fetal medicine (MFM) experts, BrightHeart goes beyond basic quality checks, delivering reliable, evidence‑backed insights that reduce diagnostic errors and improve the detection of congenital defects while strengthening workflow efficiency. BrightHeart’s AI Platform enhances Voluson’s offering with a simple, intuitive, cloud-based solution that supports enhanced care spanning acquisition, interpretation, and review across care settings and workflows.

Currently, more than 30% of congenital defects go undetected prenatally, and the U.S. is facing both a significant sonographer shortage as well as a growing number of care deserts. Studies show that structural anomalies are identified in up to 6% of pregnancies, making ultrasound a critical opportunity to inform diagnosis and care planning. Yet consistent image acquisition and interpretation remain variable, especially in resource-constrained environments.

By providing BrightHeart’s clinically validated AI to GE HealthCare’s trusted Voluson customers, this collaboration facilitates clinician access to expert-level support on their Voluson ultrasound. It empowers OB/GYNs and MFMs to perform more complete, confident exams, leading to greater consistency, earlier clarity, and smarter prenatal care at scale.

“Working closely with GE HealthCare allows us to deliver best-in-class AI tools exactly where clinicians need it within the workflows they already trust,” said Cécile Dupont, CEO of BrightHeart. “By combining our AI with Voluson ultrasound, we’re helping care teams perform more complete, efficient, and reproducible anatomy exams, reinforcing our shared commitment to elevate prenatal care.”

BrightHeart has already demonstrated significant benefit with its platform, not only improving screening capabilities and reducing errors, but also improving workflow by improving scan completeness, saving time, and increasing confidence.

“GE HealthCare is a proven leader in delivering clinically meaningful AI innovations to providers,” said Gerald Seifriedsberger, General Manager, Women’s Health Ultrasound, GE HealthCare. “Making Brightheart’s B‑Right AI platform available through the Voluson Solution Store — the first digital marketplace for Women’s Health ultrasound—puts clinically validated AI directly into the hands of Voluson customers. It helps care teams perform more complete and consistent prenatal exams and supports significantly improved performance in congenital defect screening.”


Related Content

News | Lung Imaging

Feb. 3, 2026 — RevealDx, a leader in the characterization of lung nodules, recently announced FDA clearance of RevealAI ...

Time February 04, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...

Time February 03, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Radiology Education

Jan. 22, 2026—The American Roentgen Ray Society (ARRS) will host a live virtual symposium, "Medical Imaging for ...

Time January 28, 2026
arrow
News | Point-of-Care Ultrasound (POCUS)

Jan. 27, 2026 — Siemens Healthineers and World Athletics have joined forces to inform medical teams how point-of-care ...

Time January 27, 2026
arrow
News | Radiology Imaging

Jan.26, 2026 — SimonMed Imaging has unveiled an updated brand and the launch of SimonMed Longevity, a new division ...

Time January 27, 2026
arrow
Subscribe Now